Results 261 to 270 of about 136,659 (315)

Dynamic alterations in m⁶A RNA methylation profiles during involution of infantile hemangiomas. [PDF]

Front Oncol
Wu P, Cen Q, Shang Y, Liang J, Ma G.
europepmc   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Verrucous Hemangioma: A New Mode of Presentation with Literature Review.

Indian J Dermatol
Alhamdi KI, Alhamdi DK, Almuhyi RA.
europepmc   +1 more source

A Promising Breakthrough for Triple-Negative Breast Cancer by Targeting the AKT and EZH2. [PDF]

MedComm (2020)
Liu Z, Li Y, Long X.
europepmc   +1 more source

Orders of elements in the extension of the special linear group by the inverse transpose involution

, 2015
M. A. Grechkoseeva
openalex   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Decoding infantile hemangioma: cellular dynamics, molecular signals, and microenvironmental influences. [PDF]

Front Oncol
Zhu Z, Jiang X, Wang F, Zhao L, Song Q.
europepmc   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Gradual spontaneous regression of hepatic hemangioma in a woman with surgical menopause: A decade of imaging follow-up. [PDF]

Radiol Case Rep
Leong SF, Ng IH, Lio MT, Kong SC.
europepmc   +1 more source

Fluctuation Relations Associated to an Arbitrary Bijection in Path Space. [PDF]

Math Phys Anal Geom
Chétrite R, Marcantoni S.
europepmc   +1 more source